einerseits Absturz andererseits upgrade "strong buy" von CSFB
Vancouver, Jun 13, 2001 (Stockgroup.com via COMTEX) -- A day after the FDA
delayed approval of its flagship prostate-cancer drug and had its share value
hammered by the Street, Praecis Pharmaceuticals Inc. (NASDAQ: PRCS) has received
an upgrade from 'buy' to 'strong buy' courtesy Credit Suisse First Boston.
In a research note, CSFB covering analyst Meirav Chovav says PRCS's precipitous
fall on Tuesday - down by 26.74% to close at $16.55 - represents a "buying
opportunity" for the battered biotech stock.
''We believe at the current stock price of $15-$16, no value is being paid for
Abarelix in any indication,'' Chovav said. ''If as we expect, Abarelix is
approved over the next six-12 months, the PRCS (Praecis) stock price could
easily double or triple from this point.''
If so, the buy has gotten even better. Despite Chovav's thumb's up, PRCS
continues to suffer. Today's gyrations were violent, share value bouncing
between $15.10 to $19.05 on volume of 6.39 million shares or more than 12 times
the usual volume of 548,909 shares. On Wednesday close, it had slithered to
$15.42 or off another $6.83% or $1.13.
Wer alles lesen will: quotes.freerealtime.com/rt/frt/...300164g2709&SA=Latest%20News
cdchart.innovative-software.com/informer2/...pe2=35&volumen=2" style="max-width:560px" >
Sehen wir hier bald eine techn. Gegenreaktion?
gruß der keptn
Vancouver, Jun 13, 2001 (Stockgroup.com via COMTEX) -- A day after the FDA
delayed approval of its flagship prostate-cancer drug and had its share value
hammered by the Street, Praecis Pharmaceuticals Inc. (NASDAQ: PRCS) has received
an upgrade from 'buy' to 'strong buy' courtesy Credit Suisse First Boston.
In a research note, CSFB covering analyst Meirav Chovav says PRCS's precipitous
fall on Tuesday - down by 26.74% to close at $16.55 - represents a "buying
opportunity" for the battered biotech stock.
''We believe at the current stock price of $15-$16, no value is being paid for
Abarelix in any indication,'' Chovav said. ''If as we expect, Abarelix is
approved over the next six-12 months, the PRCS (Praecis) stock price could
easily double or triple from this point.''
If so, the buy has gotten even better. Despite Chovav's thumb's up, PRCS
continues to suffer. Today's gyrations were violent, share value bouncing
between $15.10 to $19.05 on volume of 6.39 million shares or more than 12 times
the usual volume of 548,909 shares. On Wednesday close, it had slithered to
$15.42 or off another $6.83% or $1.13.
Wer alles lesen will: quotes.freerealtime.com/rt/frt/...300164g2709&SA=Latest%20News
Sehen wir hier bald eine techn. Gegenreaktion?
gruß der keptn
